My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 12

Unmet Needs and Future Perspectives of RET-Positive NSCLC

January 15, 2025

Heather A. Wakelee, MD, FASCO, Jacob Sands, MD

Panelists discuss the unmet needs and future perspectives in the treatment of RET-positive non–small cell lung cancer (NSCLC), focusing on areas for improvement in therapy and the potential for new treatment strategies.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

EP. 3: Testing Methodologies and Standards in Metastatic NSCLC

EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing

EP. 5: Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results

EP. 6: Initial Approach to Management of RET-Positive NSCLC

EP. 7: Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC

EP. 8: Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC

EP. 9: Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC

EP. 10: Managing RET Inhibitor Treatment-Related Adverse Events

EP. 11: Monitoring Patients With RET-Positive NSCLC

Now Viewing

EP. 12: Unmet Needs and Future Perspectives of RET-Positive NSCLC

Dr. Wakelee: Thank you to Dr Sands for this insightful discussion. Before we end, I would like to get some closing thoughts from Dr Sands on unmet needs and future perspectives on the treatment of RET fusion-positive NSCLC.